Publication: 316

Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial
      QxMD      Google Scholar   
Citation:
PLoS ONE vol 7 (7) e39285
Year:
2012
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
1
Parents:
384  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA035267, U10 CA052352, U10 CA037417, N01 CA035431, U10 CA035269, CA-37404, CA-35090, CA-52352, CA-35195, U10 CA037404, U10 CA035195, CA-35103, CA-25224, P50 CA116201, U10 CA035101, U10 CA063849, U10 CA035431, CA-37417, CA-35269, CA-35101, U10 CA025224, U10 CA035090, CA-35267, CA-63849, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-N004E
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Research Article, Medicine, Clinical Research Design, Clinical Trials, Phase II, Drugs and Devices, Adverse Reactions, Drug Research and Development, Oncology, Basic Cancer Research, Metastasis, Cancer Treatment, Chemotherapy and Drug Treatment, Clinical Trials (Cancer Treatment), Cancers and Neoplasms, Unknown Primary Cancer